NCT00703937View on ClinicalTrials.gov

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia

PHASE3CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

March 31, 2011

Conditions
Anemia
Interventions
DRUG

Ferric Carboxymaltose (FCM)

DRUG

Standard Medical Care (SMC) for the treatment of IDA

Trial Locations (1)

19403

Luitpold Pharmaceuticals, Norristown

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY

NCT00703937 - Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia | Biotech Hunter | Biotech Hunter